Amedeo Smart

Free Medical Literature Service

 

Amedeo

Bladder Cancer
  Free Subscription

Articles published in
Curr Opin Urol
    July 2024
  1. FAZEKAS T, Miszczyk M, Matsukawa A, Nyirady P, et al
    Defining oligometastatic state in uro-oncological cancers.
    Curr Opin Urol. 2024;34:261-265.
    >> Share

    May 2024
  2. OBIREDDY SR, Lai WF
    Advances in preclinical approaches for intravesical therapy of bladder cancer.
    Curr Opin Urol. 2024 May 17. doi: 10.1097/MOU.0000000000001186.
    >> Share

    April 2024
  3. GRAUSENBURGER R, Herek P, Shariat SF, Englinger B, et al
    Recent contributions of single-cell and spatial profiling to the understanding of bladder cancer.
    Curr Opin Urol. 2024 Apr 23. doi: 10.1097/MOU.0000000000001183.
    >> Share

  4. ERTL I, Shariat SF, Berger W, Englinger B, et al
    Preclinical models for bladder cancer therapy research.
    Curr Opin Urol. 2024 Apr 17. doi: 10.1097/MOU.0000000000001182.
    >> Share

  5. ENGLINGER B
    Molecular research in bladder cancer.
    Curr Opin Urol. 2024 Apr 12. doi: 10.1097/MOU.0000000000001181.
    >> Share

  6. NOSSING C, Herek P, Shariat SF, Berger W, et al
    Advances in preclinical assessment of therapeutic targets for bladder cancer precision medicine.
    Curr Opin Urol. 2024 Apr 11. doi: 10.1097/MOU.0000000000001177.
    >> Share

  7. ABUFARAJ M, Al Karmi J, Bdeir A
    Is there a role for metastasis-directed therapy in bladder cancer?
    Curr Opin Urol. 2024 Apr 5. doi: 10.1097/MOU.0000000000001174.
    >> Share

    March 2024
  8. CALLERIS G, von Deimling M, Kesch C, Soria F, et al
    Definitions, outcomes and perspectives for oligometastatic bladder cancer: towards a standardized terminology.
    Curr Opin Urol. 2024 Mar 1. doi: 10.1097/MOU.0000000000001170.
    >> Share

    January 2024
  9. GELIKMAN DG, Rais-Bahrami S, Pinto PA, Turkbey B, et al
    AI-powered radiomics: revolutionizing detection of urologic malignancies.
    Curr Opin Urol. 2024;34:1-7.
    >> Share

  10. IKEDA A, Nosato H
    Overview of current applications and trends in artificial intelligence for cystoscopy and transurethral resection of bladder tumours.
    Curr Opin Urol. 2024;34:27-31.
    >> Share

    November 2023
  11. CANCEL-TASSIN G, Koutros S
    Use of genomic markers to improve epidemiologic and clinical research in urology.
    Curr Opin Urol. 2023;33:414-420.
    >> Share

    July 2023
  12. DE ANGELIS M, Basile G, Scornajenghi CM, Asero V, et al
    Bladder-sparing strategies in patients with clinically localized muscle-invasive bladder cancer.
    Curr Opin Urol. 2023 Jul 3. doi: 10.1097/MOU.0000000000001113.
    >> Share

  13. YANAGISAWA T, Kawada T, von Deimling M, Laukhtina E, et al
    Need for and extent of lymph node dissection for upper tract urothelial carcinoma: an updated review in 2023.
    Curr Opin Urol. 2023;33:258-268.
    >> Share

    June 2023
  14. MELLEMA JJ, van Rhijn BWG, van der Heijden MS
    Recent developments in perioperative combination therapy in muscle-invasive bladder cancer.
    Curr Opin Urol. 2023 Jun 3. doi: 10.1097/MOU.0000000000001107.
    >> Share

    May 2023
  15. KRAJEWSKI W, Laszkiewicz J, Nowak L, Szydelko T, et al
    Current methods facilitating diagnosis of upper tract urothelial carcinoma: a comprehensive literature review.
    Curr Opin Urol. 2023;33:230-238.
    >> Share

    April 2023
  16. KATIMS AB, Bochner BH
    Extended pelvic lymph node dissection in muscle invasive bladder cancer.
    Curr Opin Urol. 2023 Apr 7. doi: 10.1097/MOU.0000000000001096.
    >> Share

    March 2023
  17. MUIN D, Laukhtina E, Hacker M, Shariat SF, et al
    PET in bladder cancer imaging.
    Curr Opin Urol. 2023 Mar 7. doi: 10.1097/MOU.0000000000001090.
    >> Share

  18. BERNDL F, Frerichmann J, Berndl T
    Prevention and management of urinary tract infections after cystectomy.
    Curr Opin Urol. 2023 Mar 3. doi: 10.1097/MOU.0000000000001085.
    >> Share

  19. WALZ S, Aslani V, Sawodny O, Stenzl A, et al
    Robotic radical cystectomy - more precision needed?
    Curr Opin Urol. 2023;33:157-162.
    >> Share

  20. TONIN E, Shariat SF, Schiavina R, Brunocilla E, et al
    En-bloc resection of non-muscle invasive bladder cancer: does it really make a difference?
    Curr Opin Urol. 2023;33:147-151.
    >> Share

    January 2023
  21. HORNAK J, Brisuda A, Babjuk M
    Transurethral resection of bladder cancer with or without fluorescence.
    Curr Opin Urol. 2023 Jan 12. doi: 10.1097/MOU.0000000000001071.
    >> Share

    December 2022
  22. KAWADA T, Yanagisawa T, Araki M, Pradere B, et al
    Sequential intravesical gemcitabine and docetaxel therapy in patients with nonmuscle invasive bladder cancer: a systematic review and meta-analysis.
    Curr Opin Urol. 2022 Dec 12. doi: 10.1097/MOU.0000000000001065.
    >> Share

    November 2022
  23. IBILIBOR C, Kennady EH, Greene KL
    The role of surgery for locally advanced urothelial cancers.
    Curr Opin Urol. 2022;32:614-617.
    >> Share

    September 2022
  24. CROCEROSSA F, Autorino R, Carbonara U, Cantiello F, et al
    Extent of lymph node dissection and impact on survival in radical cystectomy for advanced bladder cancer.
    Curr Opin Urol. 2022 Sep 14. pii: 00042307-990000000-00040.
    >> Share

  25. ESCOTT M, Avulova S, Bree KK, Westerman ME, et al
    Radical cystectomy and women's sexual health - can we do better?
    Curr Opin Urol. 2022;32:545-553.
    >> Share

  26. PIJPERS OM, de Jong JJ, Zuiverloon TCM, Boormans JL, et al
    RNA-based urinary assays for non-muscle invasive bladder cancer.
    Curr Opin Urol. 2022;32:523-530.
    >> Share

  27. COMPERAT E, Oszwald A, Wasinger G, Klager J, et al
    Molecular uropathology and cancer genetics for the urologist: key findings for classification and diagnosis.
    Curr Opin Urol. 2022;32:451-455.
    >> Share

  28. LAUKHTINA E, Pradere B, Lemberger U, Karakiewicz PI, et al
    Molecular biomarkers to help select neoadjuvant systemic therapy for urothelial carcinoma of the bladder.
    Curr Opin Urol. 2022;32:561-566.
    >> Share

  29. SHEYBAEE MOGHADDAM F, Ghoreifi A, Djaladat H
    Comparative performance of the different orthotopic urinary diversions.
    Curr Opin Urol. 2022;32:554-560.
    >> Share

  30. KIM SH, Lerner SP
    Drug instillation in the management of urinary tract urothelial carcinoma.
    Curr Opin Urol. 2022;32:531-535.
    >> Share

  31. MARTINI A, Fallara G, Ploussard G, Pradere B, et al
    Progression-free survival is an adequate endpoint for clinical trials of locally advanced and metastatic urothelial carcinoma.
    Curr Opin Urol. 2022;32:500-503.
    >> Share

  32. COMPERAT E, Wasinger G, Oszwald A, Shariat SF, et al
    Brief update of the new WHO classification for urothelial carcinoma.
    Curr Opin Urol. 2022;32:511-516.
    >> Share

  33. MESSINA E, Pisciotti ML, Pecoraro M, Borrelli A, et al
    The use of MRI in urothelial carcinoma.
    Curr Opin Urol. 2022;32:536-544.
    >> Share

    July 2022
  34. VON DEIMLING M, Pallauf M, Bianchi A, Laukhtina E, et al
    Active surveillance for non-muscle-invasive bladder cancer: fallacy or opportunity?
    Curr Opin Urol. 2022 Jul 25. pii: 00042307-990000000-00032.
    >> Share

  35. LONATI C, Simeone C, Suardi N, Briganti A, et al
    Micropapillary bladder cancer: an evolving biology.
    Curr Opin Urol. 2022 Jul 19. pii: 00042307-990000000-00030.
    >> Share

  36. SCHOBER JP, Plimack E, Geynisman D, Zibelman M, et al
    The past, present, and future of pT0 in bladder cancer clinical trials.
    Curr Opin Urol. 2022 Jul 19. pii: 00042307-990000000-00026.
    >> Share

  37. SORIA F, Dutto D, Gontero P
    Clinical and biological markers for risk-stratification of T1 high-grade non-muscle invasive bladder cancer.
    Curr Opin Urol. 2022 Jul 15. pii: 00042307-990000000-00019.
    >> Share

  38. COMPERAT E, Wasinger G, Oszwald A, Pradere B, et al
    Nonmuscle-invasive bladder cancer, old problems, new insights.
    Curr Opin Urol. 2022;32:352-357.
    >> Share

    June 2022
  39. VARTOLOMEI MD, Ferro M, Roth B, Teoh JY, et al
    Device-assisted intravesical chemotherapy treatment for nonmuscle invasive bladder cancer: 2022 update.
    Curr Opin Urol. 2022 Jun 27. pii: 00042307-990000000-00015.
    >> Share

    January 2022
  40. REGNIER S, Califano G, Elalouf V, Albisinni S, et al
    Restaging transurethral resection in ta high-grade nonmuscle invasive bladder cancer: a systematic review.
    Curr Opin Urol. 2022;32:54-60.
    >> Share

  41. HUSSEIN AA, Li Q, Guru KA
    Robot-assisted radical cystectomy: surgical technique, perioperative and oncologic outcomes.
    Curr Opin Urol. 2022;32:116-122.
    >> Share

  42. BERNDL F, Hassler MR
    Molecular intricacies of upper tract urothelial carcinoma and their relevance for therapy considerations.
    Curr Opin Urol. 2022;32:48-53.
    >> Share

  43. LONATI C, Moschini M, Simeone C, Spiess PE, et al
    Lynch syndrome in urological practice: diagnosis, therapeutic strategies, and screening for upper tract urothelial carcinoma.
    Curr Opin Urol. 2022;32:40-47.
    >> Share

    December 2021
  44. ENIKEEV D, Babjuk M, Shpikina A, Shariat S, et al
    En bloc resection for nonmuscle-invasive bladder cancer: selecting a proper laser.
    Curr Opin Urol. 2021 Dec 24. pii: 00042307-900000000-98808.
    >> Share

    November 2021
  45. CICIONE A, Lombardo R, D'Annunzio S, De Nunzio C, et al
    Success factors for abdominal wall diversions, including ureterocutaneostomy.
    Curr Opin Urol. 2021;31:544-549.
    >> Share

  46. HEESAKKERS JPFA, Witjes F
    Editorial: Medical, technical and functional aspect of various types of urinary diversion.
    Curr Opin Urol. 2021;31:542-543.
    >> Share

  47. GRAUER R, Wiklund NP
    Update on robotic cystectomy.
    Curr Opin Urol. 2021;31:537-541.
    >> Share

  48. LIEDBERG F, Bobjer J
    Urinary diversions for benign and oncologic indications: what did we learn about short term complications in the last 24 months?
    Curr Opin Urol. 2021;31:556-561.
    >> Share

  49. NUIJENS ST, Cobussen-Boekhorst H, Heesakkers JPFA, Witjes JA, et al
    Patient-reported outcomes and health-related quality of life after urinary diversions.
    Curr Opin Urol. 2021;31:574-579.
    >> Share

  50. VAN 'T HOF MEM, Bruins HM, van Roermund JGH
    Management of upper urinary tract problems after radical cystectomy for urothelial carcinoma: tips and tricks.
    Curr Opin Urol. 2021;31:570-573.
    >> Share

    July 2021

  51. Bladder-preserving strategies for Bacillus Calmette-Guerin unresponsive non-muscle invasive bladder cancer; where are we and what will be expected?: Erratum.
    Curr Opin Urol. 2021;31:436.
    >> Share

    June 2021
  52. JANSSEN GWB, Ramkumar RR, Lee BH, van der Heijden AG, et al
    Orthotopic urinary diversions after radical cystectomy for bladder cancer: lessons learned last decade.
    Curr Opin Urol. 2021 Jun 25. pii: 00042307-900000000-98856.
    >> Share

    May 2021
  53. CHAN EO, Pradere B, Teoh JY
    The use of artificial intelligence for the diagnosis of bladder cancer: a review and perspectives.
    Curr Opin Urol. 2021 May 11. pii: 00042307-900000000-98866.
    >> Share

  54. ZIMMERMANN K, Mostafaei H, Heidenreich A, Schmelz HU, et al
    Health-related quality of life in bladder cancer patients: bladder cancer-specific instruments and domains. Part 2.
    Curr Opin Urol. 2021 May 10. pii: 00042307-900000000-98868.
    >> Share

  55. SCHUETTFORT VM, Pradere B, Comperat E, Abufaraj M, et al
    Novel transurethral resection technologies and training modalities in the management of nonmuscle invasive bladder cancer: a comprehensive review.
    Curr Opin Urol. 2021 May 10. pii: 00042307-900000000-98867.
    >> Share

  56. ZIMMERMANN K, Mostafaei H, Heidenreich A, Schmelz HU, et al
    Part I. Health-related quality of life in bladder cancer patients: general and cancer-specific instruments.
    Curr Opin Urol. 2021 May 6. pii: 00042307-900000000-98874.
    >> Share

  57. PACKIAM VT, Richards J, Schmautz M, Heidenreich A, et al
    The current landscape of salvage therapies for patients with bacillus Calmette-Guerin unresponsive nonmuscle invasive bladder cancer.
    Curr Opin Urol. 2021;31:178-187.
    >> Share

  58. ABUFARAJ M, Al-Ani A, AlQudah A, Shariat SF, et al
    Surgical intervention in patients with urothelial carcinoma of the bladder and lymph node metastasis.
    Curr Opin Urol. 2021;31:220-225.
    >> Share

    April 2021
  59. PINAR U, Pradere B, Roupret M
    Artificial intelligence in bladder cancer prognosis: a pathway for personalized medicine.
    Curr Opin Urol. 2021 Apr 20. pii: 00042307-900000000-98882.
    >> Share

    December 2020
  60. HUGAR LA, Gilbert SM, Sexton WJ, Kamat AM, et al
    Immunotherapy in Bacillus Calmette-Guerin (BCG) unresponsive nonmuscle invasive bladder cancer.
    Curr Opin Urol. 2020;Publish Ahead of Print.
    >> Share

    September 2020
  61. SARI MOTLAGH R, Mori K, Aydh A, Karakiewicz PI, et al
    Impact of hospital and surgeon volumes on short-term and long-term outcomes of radical cystectomy.
    Curr Opin Urol. 2020;30:701-710.
    >> Share

  62. REBHAN K, Ertl IE, Shariat SF, Grollman AP, et al
    Aristolochic acid and its effect on different cancers in uro-oncology.
    Curr Opin Urol. 2020;30:689-695.
    >> Share

    July 2020
  63. ERTL IE, Shariat SF, Mostafaei H, Ilijazi D, et al
    Fibroblast growth factor receptors across urothelial carcinoma landscape.
    Curr Opin Urol. 2020;30:557-565.
    >> Share

  64. BRONIMANN S, Lemberger U, Bruchbacher A, Shariat SF, et al
    Poly(ADP-ribose) polymerase inhibitors in prostate and urothelial cancer.
    Curr Opin Urol. 2020;30:519-526.
    >> Share

  65. LIU B, Welk B
    Urological malignancies in neurogenic patients.
    Curr Opin Urol. 2020;30:501-506.
    >> Share

    May 2020
  66. PRADERE B, Schuettfort V, Mori K, Quhal F, et al
    Management of de-novo urothelial carcinoma in transplanted patients.
    Curr Opin Urol. 2020;30:467-474.
    >> Share

  67. JAHRREISS V, Pradere B, Laukhtina E, Mori K, et al
    Catalog of exogenous risk factors for bladder carcinogenesis.
    Curr Opin Urol. 2020;30:449-456.
    >> Share

  68. CARANDO R, Shariat SF, Moschini M, D'Andrea D, et al
    Ureteral and urethral recurrence after radical cystectomy: a systematic review.
    Curr Opin Urol. 2020;30:441-448.
    >> Share

  69. KHETRAPAL P, Conroy S, Kelly JD, Catto JWF, et al
    Comparing open-radical cystectomy and robot-assisted radical cystectomy: current status and analysis of the evidence.
    Curr Opin Urol. 2020;30:400-406.
    >> Share

  70. SUBIELA JD, Rodriguez Faba O, Guerrero-Ramos F, Aumatell J, et al
    Carcinoma in situ of the bladder: why is it underdetected?
    Curr Opin Urol. 2020;30:392-399.
    >> Share

  71. SORIA F, Giordano A, Gontero P
    Transurethral resection of bladder tumor and the need for re-transurethral resection of bladder tumor: time to change our practice?
    Curr Opin Urol. 2020;30:370-376.
    >> Share

  72. TERRITO A, Bevilacqua G, Meneghetti I, Mercade A, et al
    En bloc resection of bladder tumors: indications, techniques, and future directions.
    Curr Opin Urol. 2020;30:421-427.
    >> Share

  73. LOTAN Y
    Novel technologies that change the diagnostic and treatment paradigm in urology: standard turbt remains the standard.
    Curr Opin Urol. 2020;30:477-478.
    >> Share

  74. ALMASSI N, Bochner BH
    Ileal conduit or orthotopic neobladder: selection and contemporary patterns of use.
    Curr Opin Urol. 2020;30:415-420.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016